Instil Bio, Inc. Common Stock
TILInstil Bio, Inc. (TIL) is a biotechnology company focused on developing personalized cell therapies for cancer treatment. The company utilizes its proprietary platform to engineer and produce tumor-infiltrating lymphocyte (TIL) therapies aimed at enhancing the immune response against solid tumors. Headquartered in the United States, Instil aims to improve outcomes for cancer patients through innovative immunotherapy solutions.
Company News
Instil Bio (Nasdaq: TIL) reported Q1 2026 results with a cash position of $74.7 million, sufficient to fund operations beyond 2027. The company is actively evaluating acquisition and in-licensing opportunities to build its pipeline. R&D expenses decreased to $0.7 million from $5.4 million year-over-year, while net loss per share improved to $0.62...
Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in First Solar, Instil Bio, and Corcept Therapeutics. First Solar's stock fell 10.29% on January 7, 2026, following a Jefferies downgrade to Hold due to lowered guidance, significant de-bookings, margin compression, and limited deployment opportunities expecte...
Pomerantz LLP announced investigations into securities fraud claims on behalf of investors in three biotech companies. Zenas BioPharma's stock plummeted 51.86% following disappointing Phase 3 trial results for obexelimab, with the CEO acknowledging the drug's efficacy fell short of expectations, triggering an additional 8.49% decline. Similar inv...
Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in AST SpaceMobile, Instil Bio, and Corcept Therapeutics. The investigation into AST was triggered by a Scotiabank downgrade to Sell on January 7, 2026, citing competition from SpaceX's Starlink, slow customer adoption, and satellite launch delays. AST's stock...
Instil Bio reported a wider loss in Q2 2025, with Non-GAAP EPS of $(2.88), missing analyst expectations. The company increased R&D spending to $6.7 million and received FDA clearance for its lead drug candidate '2510, with plans to launch a U.S. clinical trial before year-end.
